On The Path To Regeneration: NovaGo’s New Approach To Stroke
Executive Summary
Zurich University spin-off NovaGo Therapeutics is taking a regenerative approach to stroke, and with €10m funding from a series A round to proceed its preclinical asset into Phase I, it is hoping to be in the clinic within two years.
You may also be interested in...
Finance Watch: New Funding Available For Antibacterials, Start-Ups
Private Company Edition: The Novo Holdings Repair Impact Fund wants to fund another round of antimicrobial resistance efforts. Also, Atlas Venture raised a new $400m fund, Everest closed a $310m series C round and Cognition received a $78.5m grant.
Beyond Aducanumab: Neurimmune Advances Portfolio Of Clinical Candidates
The Swiss firm that discovered Biogen’s Alzheimer’s therapy aducanumab has built a pipeline of clinical programs across neurological and other diseases and may seek additional partners as candidates advance.
Investment And Acquisition In Rare Diseases
In Vivo talks to investors, analysts and companies in rare disease about the challenges they face to innovate and to grow.